Screener
Immunovant, Inc. IMVT Business Segments — Other general and administrative
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherGeneralAndAdministrativeExpense.
The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.
- Filed
- May 20, 2026, 7:28 AM EDT
- Fiscal year
- FY2026
- Accession
- 0001764013-26-000064
| Line item | Years Ended March 31, 2026 | Years Ended March 31, 2025 | Years Ended March 31, 2024 |
|---|---|---|---|
| Contractual costs related to batoclimab program discontinuation | 38,952 | — | — |
| Personnel-related research and development (1) | 128,534 | 111,499 | 74,290 |
| Acquired in-process research and development | — | — | 12,500 |
| Personnel-related general and administrative (2) | 48,730 | 41,095 | 34,684 |
| Other general and administrative (3) | 27,512 | 36,140 | 22,597 |
| Interest income, net | (25,330) | (24,732) | (24,948) |
| Other segment items (4) | (1,966) | 420 | 1,575 |
| Net loss | $505,606 | $413,840 | $259,336 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Immunovant, Inc.'s business segments — other general and administrative?
- Immunovant, Inc. (IMVT) reported business segments — other general and administrative of $7.14M in Q1 2026.
- How has Immunovant, Inc.'s business segments — other general and administrative changed year-over-year?
- Immunovant, Inc.'s business segments — other general and administrative decreased by 34.4% year-over-year, from $10.88M to $7.14M.
- What is the long-term trend for Immunovant, Inc.'s business segments — other general and administrative?
- Over 3 years (2023 to 2026), Immunovant, Inc.'s business segments — other general and administrative has grown at a 11.0% compound annual growth rate (CAGR), from $20.11M to $27.51M.
- What does business segments — other general and administrative mean?
- Captures non-personnel administrative expenses such as facility costs, professional fees, insurance, and general office overhead for the segment. These costs represent the necessary operational expenditures to maintain business functions outside of direct R&D or personnel compensation. Tracking this helps assess the company's ability to control indirect operating costs.
Ask your AI about Immunovant, Inc.'s business segments — other general and administrative.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude